Widely used:Recently Viewed
Clear All$2.71
$-0.17
(-5.90%)
As on 28-Apr-2025 16:02EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
P/E Ratio
--
P/B Ratio
0.62
Industry P/E
50.24
Debt to Equity
0
ROE
-0.18 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-0.33 Mln
EBITDA
$-0.25 Mln
Net Profit
$-1.36 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
| -3.11 | -9.43 | -31.86 | -54.38 | -43.96 | -- | -- |
|
BSE Sensex*
| 2.72 | 3.82 | 5.89 | 9.01 | 11.80 | 20.14 | 11.36 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
BioNexus Gene Lab Corp Common stock (BGLC)
| -46.95 | -95.35 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 140.50 | 11,164.80 | 13.01 | 159.08 | |
| 115.32 | 11,417.38 | 23.33 | 15.7 | |
| 123.91 | 11,724.81 | 3.73 | 110.75 | |
| 172.91 | 11,345.27 | 10.21 | 17.71 |
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a... thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. Address: Tower B, Avenue 3, Kuala Lumpur, Malaysia, 59200 Read more
CEO & Director
Mr. Su-Leng Tan
CEO & Director
Mr. Su-Leng Tan
Headquarters
Kuala Lumpur
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BioNexus Gene Lab Corp Common stock (BGLC) stood at $ 18 Mln as on 31-Mar-25
The share price of BioNexus Gene Lab Corp Common stock (BGLC) is $2.71 (NASDAQ) as of 28-Apr-2025 16:02 EDT. BioNexus Gene Lab Corp Common stock (BGLC) has given a return of -43.96% in the last 3 years.
BioNexus Gene Lab Corp Common stock (BGLC) has a market capitalisation of $ 5 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of BioNexus Gene Lab Corp Common stock (BGLC) is 0.62 times as on 28-Apr-2025, a 76% discount to its peers’ median range of 2.59 times.
Since, TTM earnings of BioNexus Gene Lab Corp Common stock (BGLC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioNexus Gene Lab Corp Common stock (BGLC) and enter the required number of quantities and click on buy to purchase the shares of BioNexus Gene Lab Corp Common stock (BGLC).
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. Address: Tower B, Avenue 3, Kuala Lumpur, Malaysia, 59200
The CEO & director of Mr. Su-Leng Tan. is BioNexus Gene Lab Corp Common stock (BGLC), and CFO & Sr. VP is Mr. Su-Leng Tan.
There is no promoter pledging in BioNexus Gene Lab Corp Common stock (BGLC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,142
|
|
|
1,111
|
|
|
1,052
|
|
|
1,014
|
| BioNexus Gene Lab Corp Common stock (BGLC) | Ratios |
|---|---|
|
Return on equity(%)
|
-20.81
|
|
Operating margin(%)
|
-15.48
|
|
Net Margin(%)
|
-19.09
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BioNexus Gene Lab Corp Common stock (BGLC) was $0 Mln.
